biosimilar portfolio
Scope
Date
~
-
Mergers & Acquisitions
Harman acquires Masimo’s audio arm in Samsung’s car audio push
Harman International Industries Inc., wholly owned by Samsung Electronics Co., has acquired Masimo Corp.’s audio business for $350 million, a ...
May 07, 2025 (Gmt+09:00)
-
Bio & Pharma
Korea’s pharmaceutical exports set to top $10 bn, led by ‘K-M7’ champions
South Korea’s pharmaceutical exports are on course to surpass $10 billion this year, underscoring the country’s growing clout in the glo...
May 05, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion expands footprint in Latin America with flagship oncology drugs
South Korea’s biopharmaceutical giant Celltrion Inc. has solidified its presence in South America after winning supply contracts for its flags...
Apr 17, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins Australian approval for eye, bone disease biosimilars
Celltrion Inc. said Wednesday it has received regulatory approval from Australia’s Therapeutic Goods Administration (TGA) for three biosimilar...
Apr 10, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US
South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...
Mar 25, 2025 (Gmt+09:00)
-
Cryptocurrencies
BlackRock sees digital assets at critical turning point
Digital assets are poised for robust structural growth – not just as investment vehicles but as strategic assets – fueled by growing ins...
Mar 25, 2025 (Gmt+09:00)
-
Pension funds
S.Korea’s NPS to double pension fund size by 2050, hike risky assets
South Korea’s National Pension Service (NPS) is projected to nearly double its fund size to 3,500 trillion won ($2.38 trillion) by 2050, follo...
Mar 24, 2025 (Gmt+09:00)
-
Batteries
LG Energy, Doosan Bobcat tie up for construction equipment battery packs
LG Energy Solution Ltd., the world’s third-largest battery maker, and Doosan Bobcat Inc., a global construction machinery producer, said on We...
Mar 19, 2025 (Gmt+09:00)
-
Pension funds
S.Korea’s pension fund NPS to overhaul alternative investment strategy
The National Pension Service (NPS), South Korea’s state-run pension fund and the country’s largest institutional investor, plans to intr...
Mar 12, 2025 (Gmt+09:00)
-
Bio & Pharma
Samsung, Celltrion lead biosimilar market in Europe, US
Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz in the antibody biosim...
Mar 10, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins EU approval for autoimmune disease treatment Avtozma
Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...
Feb 25, 2025 (Gmt+09:00)
-
Bio & Pharma
Korean court rules in favor of Samsung Bioepis over Regeneron’s Eylea
A South Korean court on Friday ruled in favor of Samsung Bioepis Co. in a patent dispute against Regeneron Pharmaceuticals Inc., a US pharmaceutical...
Feb 21, 2025 (Gmt+09:00)
-
Corporate restructuring
SK Ecoplant seeks to sell waste treatment business for $1.4 billion
SK Ecoplant Co., a South Korean construction engineering and waste management company under SK Group, is seeking to dispose of its waste treatment b...
Feb 12, 2025 (Gmt+09:00)
-
Corporate investment
LX International seeks to acquire nickel, copper mines in Indonesia
LX International Corp., the trading unit of South Korea’s LX Group, said on Friday it is seeking to acquire a nickel mine and a copper mine in...
Feb 07, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe
South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...
Feb 05, 2025 (Gmt+09:00)
-
Bio & Pharma
Korean drugmakers control more than half of European biosimilar market
South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar...
Jan 02, 2025 (Gmt+09:00)
-
Bio & Pharma
Celltrion obtains approval of Steqeyma from FDA
South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...
Dec 18, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s 4 new biosimilars win EU approval recommendation
Celltrion Inc. is one step closer to commercializing its four new biosimilars in Europe after a committee of the European Medicines Agency (EMA) rec...
Dec 16, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets approval of Omlyclo in Canada
South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Omlyclo, the biosimilar of allergic asthma an...
Dec 09, 2024 (Gmt+09:00)
-
Executive reshuffles
SK promotes restructuring keymen to SK On, SK Discovery top posts
SK Group on Thursday promoted the keymen of its business overhauls to top posts at intermediary holding company SK Discovery Co. and battery maker S...
Dec 05, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion to break ground on CDMO plant in 2025: Chairman Seo
South Korea’s leading biosimilar developer Celltrion Inc. will break ground on its first contract development and manufacturing organization (...
Nov 28, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug
Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...
Nov 25, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis gets EC's approval for Opuviz
South Korea's Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, and the US-based Biogen said on Tuesday the European C...
Nov 19, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion releases Steqeyma in Europe
South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...
Nov 05, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
SK Nexilis poised to sell thin film division to Affirma Capital
SK Nexilis Co., the world’s largest copper foil maker, is in the final stage of negotiations to sell its thin film manufacturing division to A...
Oct 30, 2024 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis eyes record sales in 2024 after stellar Q3
Samsung Bioepis Co., Samsung Biologics Co.'s fully owned biosimilar subsidiary, is expected to post its best-ever annual revenue this year after sal...
Oct 24, 2024 (Gmt+09:00)
-
Corporate strategy
Apparel maker Hansae sets sights on auto parts business as growth driver
HO CHI MINH CITY – South Korean apparel maker Hansae Yes24 Group has set its sights on the auto parts business as a new growth driver to diver...
Oct 16, 2024 (Gmt+09:00)
-
Mergers & Acquisitions
Sono Hospitality to buy stake in Air Premia to bolster airline portfolio
Sono Hospitality Group, South Korea’s largest resort operator, will add low-cost carrier Air Premia Inc. to its bulging portfolio after agreei...
Oct 15, 2024 (Gmt+09:00)
-
Batteries
LG Energy aims to more than double sales to $50 billion by 2028
LG Energy Solution Ltd. has vowed to more than double its sales in five years to 67 trillion won ($50 billion) by diversifying its battery products ...
Oct 07, 2024 (Gmt+09:00)
-
Bio & Pharma
Celltrion earmarks billions of dollars to build CDMO plant: chairman
Celltrion Inc., South Korea’s largest biosimilar maker, will spend several billion dollars to build a factory to crack the contract developmen...
Sep 11, 2024 (Gmt+09:00)
Latest News
- 1 Korea’s top cinema chains seek merger to counter box office slump
- 2 S.Korea’s GEPS to commit $143 million to foreign mid-cap buyout funds
- 3 CJ CheilJedang to open $72 mn dumpling plant in Japan
- 4 LG Electronics breaks ground on $600 million home appliance plant in India
- 5 KakaoBank posts record Q1 profit, eyes Thai expansion after Indonesia